Abstract

The species Bifidobacterium animalis populates the mammalian colon and grows well in milk; as a consequence, strains from these species have been isolated from milk cultures. Its resistance to acid and oxidative stress renders strains from these species ideally suited to their formulation in fermented milk products. Laboratory studies have identified a number of properties that could be clinically relevant: immune modulation, epithelial adherence, and enhancement of gut barrier function. Two commercially available strains have been studied extensively: B. animalis spp. lactis BB-12 and B. animalis spp. lactis DN-173 010. The latter has been shown to accelerate gut transit in man and to provide symptom relief to individuals with common gastrointestinal symptoms, irritable bowel syndrome and constipation, while the former has shown some promise in boosting the immune response in man.

Original languageEnglish (US)
Title of host publicationThe Microbiota in Gastrointestinal Pathophysiology
Subtitle of host publicationImplications for Human Health, Prebiotics, Probiotics, and Dysbiosis
PublisherElsevier
Pages127-130
Number of pages4
ISBN (Electronic)9780128040621
ISBN (Print)9780128040249
DOIs
StatePublished - Jan 1 2017

Keywords

  • Bifidobacterium animalis
  • Bifidobacterium animalis spp. lactis BB-12
  • Bifidobacterium animalis spp. lactis DN-173 010
  • Colon transit
  • Immune response
  • Irritable bowel syndrome

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Bifidobacterium animalis spp. lactis'. Together they form a unique fingerprint.

Cite this